MannKind Corporation

MannKind Corporationverified

MNKD

Price:

$6.74

Market Cap:

$1.86B

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), a synthetic form of human vasoactive intestinal peptide to help protect ...[Read more]

Industry

Biotechnology

IPO Date

2004-07-28

Stock Exchange

NASDAQ

Ticker

MNKD

The Enterprise Value as of December 2024 (TTM) for MannKind Corporation (MNKD) is 2.04B

According to MannKind Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 2.04B. This represents a change of 35.35% compared to the average of 1.50B of the last 4 quarters.

MannKind Corporation (MNKD) Historical Enterprise Value (quarterly & annually)

How has MNKD Enterprise Value performed in the past?

The mean historical Enterprise Value of MannKind Corporation over the last ten years is 879.15M. The current 2.04B Enterprise Value has changed 23.07% with respect to the historical average. Over the past ten years (40 quarters), MNKD's Enterprise Value was at its highest in in the June 2015 quarter at 2.43B. The Enterprise Value was at its lowest in in the December 2018 quarter at 230.01M.

Quarterly (TTM)
Annual

Average

879.15M

Median

710.96M

Minimum

184.11M

Maximum

1.94B

MannKind Corporation (MNKD) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of MannKind Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 119.05%

Maximum Annual Enterprise Value = 1.94B

Minimum Annual Increase = -65.48%

Minimum Annual Enterprise Value = 184.11M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20231.12B-33.10%
20221.67B23.76%
20211.35B78.96%
2020753.12M119.05%
2019343.81M86.74%
2018184.11M-47.96%
2017353.77M-15.50%
2016418.65M-37.40%
2015668.81M-65.48%
20141.94B18.51%

MannKind Corporation (MNKD) Average Enterprise Value

How has MNKD Enterprise Value performed in the past?

The current Enterprise Value of MannKind Corporation (MNKD) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

1.38B

5-year avg

1.05B

10-year avg

879.15M

MannKind Corporation (MNKD) Enterprise Value vs. Peers

How is MNKD’s Enterprise Value compared to its peers?

MannKind Corporation’s Enterprise Value is less than BioMarin Pharmaceutical Inc. (12.63B), less than Vaxcyte, Inc. (9.69B), greater than Liquidia Corporation (774.18M), less than Legend Biotech Corporation (5.90B), less than Bio-Techne Corporation (11.82B), less than United Therapeutics Corporation (14.96B), greater than Larimar Therapeutics, Inc. (211.48M), greater than Day One Biopharmaceuticals, Inc. (857.57M), greater than Kiniksa Pharmaceuticals, Ltd. (1.35B), greater than Verastem, Inc. (101.83M), less than ImmunoGen, Inc. (8.19B), greater than Immutep Limited (365.43M), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Elevation Oncology, Inc. (16.16M), less than Acer Therapeutics Inc. (0), greater than NRx Pharmaceuticals, Inc. (17.56M), greater than Pasithea Therapeutics Corp. (24.01M), greater than SAB Biotherapeutics, Inc. (-6092141.00), greater than MiNK Therapeutics, Inc. (33.19M), greater than Affimed N.V. (19.21M), greater than Adaptimmune Therapeutics plc (23.62M), greater than Sangamo Therapeutics, Inc. (55.99M), greater than null (510.14M),

Build a custom stock screener for MannKind Corporation (MNKD) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like MannKind Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

MannKind Corporation (MNKD) and other stocks custom spreadsheet templates

The easiest way to analyze a company like MannKind Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is MannKind Corporation's Enterprise Value?

What is the highest Enterprise Value for MannKind Corporation (MNKD)?

What is the 3-year average Enterprise Value for MannKind Corporation (MNKD)?

What is the 5-year average Enterprise Value for MannKind Corporation (MNKD)?

How does the current Enterprise Value for MannKind Corporation (MNKD) compare to its historical average?